



**GlucTrack®**

## **Integrity Applications, GlucTrack® Innovator, Expands Board of Directors with the Appointment of Michael Hauck**

Wilmington, Delaware, and Ashdod, Israel, May 25, 2017 /PRNewswire/ — Integrity Applications, Inc. (OTCQB: IGAP), maker of GlucTrack®, a non-invasive device for measuring glucose levels of people with type 2 diabetes and prediabetes, today announced the appointment of Michael Hauck to its Board of Directors.

John Graham, CEO and Chairman of Integrity Applications, remarked, “We are honored to welcome Mr. Hauck to Integrity Application’s Board of Directors during this exciting stage in our Company’s growth. His expansive knowledge of international markets, worldwide distribution and healthcare service solutions, will be invaluable as we expand GlucTrack’s global footprint in the rapidly growing diabetes and glucose monitoring landscape.”

Mr. Hauck is currently the Executive Director of The Getz Group, a privately owned pan-Asian trading company focused on healthcare, industrial products, consumer distribution and retailing. He previously held executive and director level positions at various companies including, ERM, Interpharma Investments Ltd, Invida Holdings, Target Worldwide Express, 3i plc, Springboard, and Business Health Group Ltd. Mr. Hauck also served as the CEO of Walsh International for eight years, where he led the company’s IPO and eventual sale to IMS Health.

Mr. Hauck commented, “I am delighted to be a part of Integrity Applications, which is changing the way glucose is monitored and diabetes is managed. I am excited about the prospects for the company’s innovative non-invasive glucose monitoring technology, GlucTrack, to transform diabetes management, but especially the potential to expand its offering to provide valuable data and insights to healthcare professionals. I look forward to working with the Integrity Applications team as the company continues its expansion.”

### **About GlucTrack®**

GlucTrack® is a truly non-invasive monitoring device that rapidly measures and displays an individual’s glucose level in about a minute without finger pricking or any pain.

GlucTrack® features a small sensor that clips to the earlobe and measures the user’s glucose level using innovative and patented sensor technology. The measured signals are analyzed using a proprietary algorithm and then a calculated glucose level is displayed on a small handheld device

the size of a small mobile phone. The glucose results are stored in the device and used for a projected HbA1c level using a proprietary algorithm. The device also displays the glucose values graphically allowing the user to monitor glucose over a period of time.

GlucoTrack® has received CE Mark and KFDA approvals for type 2 diabetes and prediabetics, and is currently in the early stages of commercialization in Europe, South Korea and other geographies.

GlucoTrack® is expected to begin clinical trials for United States FDA approval in late 2017. The product is currently experimental in the United States and is limited to investigational use only.

### **About Integrity Applications, Inc.**

Integrity Applications was founded in 2001 and is focused on the design, development and commercialization of non-invasive glucose monitoring technologies for patients with diabetes and prediabetes. The company has developed GlucoTrack®, a proprietary non-invasive glucose monitoring device designed to obtain glucose level measurements in about a minute without the pain, incremental cost, difficulty or discomfort of conventional invasive finger stick devices. Integrity Applications Inc. is a Delaware corporation, with headquarters in the United States and an R&D site in Ashdod, Israel. For more information, please visit [www.integrity-app.com](http://www.integrity-app.com) and [www.glucotrack.com](http://www.glucotrack.com).

### **Forward-Looking Statements**

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “expect”, “plan” and “will” are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect Integrity Applications’ actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect Integrity Applications’ results include, but are not limited to, the ability of Integrity Applications to raise additional capital to finance its operations (whether through public or private equity offerings, debt financings, strategic collaborations or otherwise); risks relating to the receipt (and timing) of regulatory approvals (including FDA approval); risks relating to enrollment of patients in, and the conduct of, clinical trials; risks relating to its current and future distribution agreements; risks relating to its ability to hire and retain qualified personnel, including sales and distribution personnel; and the additional risk factors described in Integrity Applications’ filings with the U.S. Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K for the year ended December 31, 2016 as filed with the SEC on March 30, 2017.

### **MEDIA CONTACTS**

Erich Sandoval / Amy Wheeler

Lazar Partners Ltd.

[esandoval@lazarpartners.com](mailto:esandoval@lazarpartners.com) / [awheeler@lazarpartners.com](mailto:awheeler@lazarpartners.com)

+1 (917) 497-2867 / +1 (646) 871-8486

### **INVESTOR CONTACTS**

Matthew Ventimiglia  
Lazar Partners Ltd.  
[mventimiglia@lazarpartners.com](mailto:mventimiglia@lazarpartners.com)  
+1 (212) 599-1265

Sami Sassoun, CFO Integrity Applications  
[SamiS@integrity-app.com](mailto:SamiS@integrity-app.com)  
+972 (8) 675-7878 Ext. 400

###